论文部分内容阅读
[目的]探讨复方苦参注射液联合多西他赛对一线化疗失败非小细胞肺癌(NSCLC)患者的疗效及血清肿瘤标记物的影响.[方法]80例一线化疗失败的NSCLC患者随机分为观察组(复方苦参注射液+多西他赛)与对照组(多西他赛),比较两组近期疗效、不良反应、治疗前后血清肿瘤标记物水平及细胞免疫功能变化,并随访统计两组总生存期(OS)、无进展生存期(PFS).[结果]观察组近期有效率和疾病控制率分别为25.00%(10/25)和62.50%(25/40),明显高于对照组的10.00%(4/40)和37.50%(15、40),且差异有显著性(P0.05);与治疗前比较,两组治疗后血清癌胚抗原(CEA)、糖类抗原-125(CA-125)、细胞角蛋白19片段(CYFRA21-1)水平均显著下降(P<0.05),且观察组治疗后上述指标均显著低于对照组(P<0.05);观察组中位OS、PFS分别为13.50个月、9.00个月,明显长于对照组的10.20个月、7.40个月,且差异有显著性(P<0.05).[结论]复方苦参注射液联合多西他赛能明显降低NSCLC患者血清肿瘤标记物,改善机体细胞免疫功能,延长OS、PFS,且不增加毒副反应.“,”[Objective]To investigate the effect of compound Kushen injection combined with Docetaxel on ser-um tumor markers in patients with non-small cell lung cancer(NSCLC)after the failure of first-line chemotherapy treatment.[Methods]A total of 80 patients with NSCLC after the failure of first-line chemotherapy treatment were randomly divided into observation group(treated with compound Kushen injection combined with docetaxel) and control group(treated with docetaxel).The short-term efficacy,adverse reactions,serum tumor markers lev-els before and after treatment and changes of cellular immune function were compared between the two groups,OS and PFS of the two groups were statistically analyzed.[Results] The short-term effective rate and disease control rate of the observation group were 25%(10/25)and 62.50%(25/40),respectively,which were significantly higher than 10%(4/40)and 37.50%(15,40)of the control group,and the difference was significant(P 0.05);Compared with before treatment,the levels of serum carcinoembryonic antigen(CEA),carbohydrate anti-gen-125(CA-125)and cytokeratin 19 fragment(CYFRA21-1)were significantly decreased in the two groups af-ter treatment(P <0.05),and the above indexes in the observation group were significantly lower than those in the control group(P <0.05);The median OS and PFS in the observation group were 13.50 months and 9 months respectively,which were significantly longer than those in the control group at 10.20 months and 7.40 months, and the difference was significant(P <0.05).[Conclusion]Compound Kushen injection combined with docetaxel can significantly reduce the serum tumor markers in patients with NSCLC,improve the cellular immune function, prolong OS,PFS,and do not increase toxicity.